Search

Your search keyword '"Liu, Dai-Hong"' showing total 603 results
Start Over Author "Liu, Dai-Hong"
603 results on '"Liu, Dai-Hong"'

103. Effect of Transfusion of the Third Party Umbilical Cord Blood on Haplo-Identical Hematopoietic Stem Cell Transplantation

Author

Wang, Jing Bo, primary, Fei, Xin Hong, additional, Cheng, Hao Yu, additional, Yin, Yu Ming, additional, Zhang, Wei Jie, additional, Zhang, Shu Qin, additional, Li, Qian, additional, Xue, Song, additional, Gu, Jiang Ying, additional, He, Jun Bao, additional, Yang, Fan, additional, Liu, Meng Qi, additional, Zhao, Jie, additional, and Liu, Dai-Hong, additional

Published
2015
Full Text
View/download PDF

104. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of patients with mixed-lineage-leukemia-rearranged acute leukemia: Results from a prospective, multi-center study

Author

Yu, Wang, Wang, Yu, Qi-Fa, Liu, Liu, Qi-Fa, Ya-Zhen, Qin, Qin, Ya-Zhen, Dai-Hong, Liu, Liu, Dai-Hong, Lan-Ping, Xu, Xu, Lan-Ping, Bin, Jiang, Jiang, Bin, Qian, Jiang, Jiang, Qian, Min, Dai, Dai, Min, Si-Jian, Yu, Yu, Si-Jian, Xin-Miao, Jiang, Jiang, Xin-Miao, Yan-Rong, Liu, Liu, Yan-Rong, Xiao-Jun, Huang, and Huang, Xiao-Jun

Subjects
Adult, Male, Transplantation Conditioning, Adolescent, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Middle Aged, Chemoprevention, Transplantation, Autologous, Tissue Donors, Translocation, Genetic, Leukemia, Biphenotypic, Acute, Young Adult, Treatment Outcome, Recurrence, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Humans, Transplantation, Homologous, Female, Prospective Studies, Child
Abstract

The purpose of this study is to define the role for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in mixed-lineage-leukemia (MLL)-rearranged acute leukemia, which is now poorly understood. A prospective, multi-center cohort study to determine whether allo-HSCT could decrease relapse rates and improve long-term survival of MLL+ leukemia patients was performed. Fifty-six consecutive patients diagnosed with MLL-rearranged acute leukemia undergoing allo-HSCT from two transplant centers in China were enrolled between October 2007 and October 2012. The trial was registered at www.chictr.org as # ChiCTR-ONC-12002739. The incidences of grades II to IV acute graft versus host disease (aGVHD) and of grades III and IV aGVHD were 28.8% (CI, 16.87-40.8%), and 14.2% (CI, 5.4-23.0%), respectively. The cumulative incidences for chronic GVHD (cGVHD) at 2 years after HSCT were 35.2% (CI, 21.2-49.2%). Up to April 30, 2013, 12 patients had relapsed and 11 died from relapse, and 37 patients were still alive without disease recurrence. The relapse and NRM rates at 3 years were 25.3% (CI, 12.7-37.9%) and 18.0% (CI, 2.6-33.4%), respectively. The probalities of overall survival and leukemia free survival were 61.8% (CI, 46.0-77.6%) and 56.3% (CI, 38.1-74.5%) at 3 years, respectively. Patients transplanted during their hematological first complete remission (CR1) had a lower relapse rate (17.9% vs. 48.1%, P = 0.03) compared with patients transplanted beyond CR1. The median overall survival for the 29 patients not receiving allo-HSCT during the study period was 145 days from diagnosis. This study showed that allo-HSCT could be a valuable treatment choice for MLL+ acute leukemia.

Published
2013

105. Risk-Stratification Directed Prophylaxis with Additional Low-Dose of Methylprednisolone Can Reduce Acute Graft-Versus-Host Disease for Patients with Hematological Malignancies after Allogeneic SCT: A Randomized, Controlled, Clinical Trial

Author

Chang, Ying-Jun, primary, Wang, Yu, additional, Xu, Lan-Ping, additional, Liu, Dai-Hong, additional, Liu, Kai-Yan, additional, Zhang, Xiao-Hui, additional, Tang, Fei-Fei, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Mo, Xiao-Dong, additional, Han, Wei, additional, Yan, Chen-Hua, additional, Wang, Feng-Rong, additional, Sun, Yu-Qian, additional, and Huang, Xiao Jun, additional

Published
2014
Full Text
View/download PDF

107. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies

Author

Chen Yuhong, Han Wei, Chen Yao, Wang Feng-Rong, Shi Hong-Xia, Chen Huan, Wang Yu, Tang Fei-Fei, Wang Jing-Zhi, Liu Dai-Hong, Huang Xiaojun, Liu Kaiyan, Xu Lanping, and Zhang Xiaohui

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Graft vs Host Disease, Hematopoietic stem cell transplantation, Gastroenterology, Young Adult, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Outcome Assessment, Health Care, Medicine, Humans, Child, Survival rate, Survival analysis, Leukemia, business.industry, Incidence (epidemiology), Histocompatibility Testing, Hematopoietic Stem Cell Transplantation, Middle Aged, Survival Analysis, Confidence interval, Tissue Donors, Surgery, Transplantation, Survival Rate, Oncology, Relative risk, Child, Preschool, Hematologic Neoplasms, Cohort, Acute Disease, Multivariate Analysis, Female, business
Abstract

Purpose: The study aimed to compare the outcomes of patients undergoing hematopoietic stem cell transplantation (HSCT) from partially matched related donors (PMRD) and unrelated donors (URD) for hematologic malignancies without the use of in vitro T cell depletion. Experimental Design: HSCT was done on 297 consecutive patients from URDs (n = 78) and PMRDs (n = 219) during the same time period. Incidences of graft-versus-host disease (GVHD), relapse, nonrelapse mortality, overall survival, and leukemia-free survival between the PMRD and URD groups were compared. Results: All patients achieved full engraftment. The cumct65ulative incidences of grades II to IV acute GVHD in the PMRD and URD cohorts were 47% [95% confidence interval (95% CI), 33-62%] versus 31% (CI, 20-42%; P = 0.033), with a relative risk of 1.72 (95% CI, 1.01-2.94; P = 0.046). The incidence of chronic GVHD did not differ significantly between the two cohorts (P = 0.17). The 2-year incidences of nonrelapse mortality and relapse were 20% (CI, 15-26%) versus 18% (CI, 10-27%), with P = 0.98, and 12% (CI, 8-16%) versus 18% (CI, 10-27%), with P = 0.12, for the PMRD versus the URD cohort, respectively. The 4-year overall survival and leukemia-free survival were 74% (CI, 67-80%) versus 74% (CI, 62-85%), with P = 0.98, and 67% (CI, 59-75%) versus 61% (CI, 47-74%), with P = 0.74, respectively. Conclusions: Our comparisons show that every major end point, including relapse, nonrelapse mortality, overall survival, and leukemia-free survival, was comparable between the PMRD and the URD groups.

Published
2009

109. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase

Author

Wang Jing-Zhi, Liu Dai-Hong, Han Wei, Shi Hong-Xia, Xu Lanping, Chen Yao, Liu Kaiyan, Lu Dao-Pei, Huang Xiaojun, Zhang Xiaohui, Chen Huan, and Chen Yuhong

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Transplantation Conditioning, Cyclophosphamide, Adolescent, medicine.medical_treatment, Graft vs Host Disease, Hematopoietic stem cell transplantation, Opportunistic Infections, Young Adult, Directed Tissue Donation, hemic and lymphatic diseases, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Humans, Transplantation, Homologous, Child, business.industry, Histocompatibility Testing, Graft Survival, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, General Medicine, Middle Aged, medicine.disease, Survival Analysis, Transplantation, Leukemia, surgical procedures, operative, medicine.anatomical_structure, Immunology, Female, Bone marrow, business, Blast Crisis, Busulfan, medicine.drug, Chronic myelogenous leukemia
Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only proven curative therapy for chronic myeloid leukemia (CML), but lack of human leukocyte antigen (HLA)-matched sibling or unrelated donors has restricted its application. Recently, we developed an effective method for haploidentical allo-HSCT achieving comparable outcomes to HLA-identical transplantation.To evaluate the outcomes of CML patients who underwent haploidentical allo-HSCT.Ninety-three patients were treated with a modified busulfan (BU)/cyclophosphamide (CY) 2 regimen, including antithymocyte globulin followed by unmanipulated blood and marrow transplantation.Our data showed that the cumulative incidence of acute graft-versus-host disease (GVHD) was 64.52%, and grade III-IV was 26.45%, 61.79% had chronic GVHD, and 28.93% had extensive chronic GVHD. Non-relapse mortality varied at 8.72% (100 days), 20.72% (1 year) and 20.72% (2 years). Probability of 1-year and 4-year leukemia-free survival was similar in chronic phase (CP) 1, CP2/CR2, accelerated phase, and blast crisis patients. Probability of 4-year overall survival varied as 76.5% (CP1), 85.7% (CP2/CR2), 73.3% (accelerated phase), and 61.5% (blast crisis). Multivariate analysis indicated that factors affecting transplantation outcomes were HLA-B+DR mismatches versus others for II-III acute GVHD and III-IV acute GVHD, the stage of disease at transplantation for relapse, and the time from diagnosis to transplantation for leukemia-free survival, overall survival, and transplantation-related mortality. In our protocol, survival of HSCT for advanced CML was similar to stable stage.For patients lacking an HLA-identical related donor, haploidentical relatives are alternative HSCT donors.

Published
2008

110. Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies.

Author

Li, Hong‐Hua, Li, Fei, Gao, Chun‐Ji, Huang, Wen‐Rong, Bo, Jian, Dou, Li‐Ping, Wang, Li‐Li, Jing, Yu, Wang, Lu, Li, Wen‐Jun, Yu, Li, and Liu, Dai‐Hong

Subjects
GRAFT versus host disease, STEM cell transplantation, HAPLOIDY, STEM cell donors, IMMUNOGLOBULINS
Abstract

The features of graft-versus-host disease ( GVHD) were compared between patients who underwent myeloablative conditioning and received a peripheral blood stem cell transplant ( PBSCT) from either a haploidentical donor ( HID) or a matched sibling donor ( MSD) during the same period of time. The HID group included more patients with advanced disease. Both groups received the same GVHD prophylaxis with the addition of antithymoglobulin ( ATG) in HID group. Higher cumulative incidences ( CI) of acute GVHD grade 2-4 (35·1% vs. 13·9%, P = 0·003), similar CI of grade 3-4 (14·5% vs. 9·8%, P = 0·595), less 3-year CI of extensive chronic GVHD (17·1% vs. 41·5%, P = 0·017) and less severe chronic GVHD (5·8% vs. 21·2%, P = 0·049) occurred in the HID group compared with the MSD group. There was no difference in the sites of the involved organs between these two groups. Higher 3-year CI of non-relapse mortality (24·0% vs. 10·2%, P = 0·014), relapse (39·0% vs. 22·6%, P = 0·032) and inferior disease-free survival (45·7% vs. 78·9%, P = 0·000) were recorded in the HID cohort compared with the MSD group. More HID patients had Karnofsky scores above 90 than those in MSD group ( P = 0·016). In conclusion, ATG plays a key role in the unmanipulated HID PBSCT protocol, producing better quality of life in survivors. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

111. Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia‐negative acute lymphoblastic leukemia: No difference in the high‐ and low‐risk groups

Author

Mo, Xiao‐Dong, primary, Xu, Lan‐Ping, additional, Zhang, Xiao‐Hui, additional, Liu, Dai‐Hong, additional, Wang, Yu, additional, Chen, Huan, additional, Yan, Chen‐Hua, additional, Chen, Yu‐Hong, additional, Han, Wei, additional, Wang, Feng‐Rong, additional, Wang, Jing‐Zhi, additional, Liu, Kai‐Yan, additional, and Huang, Xiao‐Jun, additional

Published
2014
Full Text
View/download PDF

112. Who is the best donor for a related HLA haplotype-mismatched transplant?

Author

Wang, Yu, primary, Chang, Ying-Jun, additional, Xu, Lan-Ping, additional, Liu, Kai-Yan, additional, Liu, Dai-Hong, additional, Zhang, Xiao-Hui, additional, Chen, Huan, additional, Han, Wei, additional, Chen, Yu-Hong, additional, Wang, Feng-Rong, additional, Wang, Jing-Zhi, additional, Chen, Yao, additional, Yan, Chen-Hua, additional, Huo, Ming-Rui, additional, Li, Dan, additional, and Huang, Xiao-Jun, additional

Published
2014
Full Text
View/download PDF

113. Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial

Author

Han, Ting-ting, primary, Xu, Lan-ping, additional, Liu, Dai-hong, additional, Liu, Kai-yan, additional, Wang, Feng-rong, additional, Wang, Yu, additional, Yan, Chen-hua, additional, Chen, Yu-hong, additional, Sun, Yu-qian, additional, Ji, Yu, additional, Wang, Jing-zhi, additional, Zhang, Xiao-hui, additional, and Huang, Xiao-jun, additional

Published
2014
Full Text
View/download PDF

115. CD34+CD38-CD58- Candidate Leukemia-Initiating Cells Are Clinically Relevant With The Unfavorable Prognosis In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Author

kong, Yuan, primary, Chang, Ying-Jun, additional, Liu, Yan-rong, additional, Wang, Ya-zhe, additional, Jiang, Qian, additional, Jiang, Hao, additional, Qin, Ya-Zhen, additional, Wang, Jing, additional, Zhu, Hong-Hu, additional, Lai, Yue-Yun, additional, Xu, Lanping, additional, Liu, Dai-Hong, additional, and Huang, Xiao-Jun, additional

Published
2013
Full Text
View/download PDF

116. Effects Of Noninherited Maternal Antigen On The Occurrence Of Acute Graft-Versus Host Diseae After Unmanipulated Haploidentical Blood and Marrow Transplantation

Author

Chang, Ying-Jun, primary, Liu, Dai-Hong, additional, Liu, Kaiyan, additional, Xu, Lan-Ping, additional, Wang, Yu, additional, Huo, Ming-Rui, additional, Chen, Huan, additional, Han, Wei, additional, Chen, Yu-Hong, additional, Wang, Feng-Rong, additional, Wang, Jing-Zhi, additional, Chen, Yao, additional, Yan, Chen-Hua, additional, and Huang, Xiao-Jun, additional

Published
2013
Full Text
View/download PDF

117. Low WT1 Expression At Diagnosis Is a Strong Predictor On Poor Outcome In Patients With t(8;21) Acute Myeloid Leukemia

Author

Qin, Ya-Zhen, primary, Zhu, Hong-Hu, additional, Jiang, Qian, additional, Liu, Dai-Hong, additional, Jiang, Hao, additional, Xu, Lan-Ping, additional, Chen, Huan, additional, Wang, Yu, additional, Zhang, Xiao-hui, additional, MM, Jun-Yue Chai, additional, Wang, Li-Ru, additional, Liu, Yan-Rong, additional, and Huang, Xiao-Jun, additional

Published
2013
Full Text
View/download PDF

119. Heart failure after allogeneic hematopoietic stem cell transplantation

Author

Mo, Xiao-Dong, primary, Xu, Lan-Ping, additional, Liu, Dai-Hong, additional, Zhang, Xiao-Hui, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Han, Wei, additional, Wang, Yu, additional, Wang, Feng-Rong, additional, Wang, Jing-Zhi, additional, Zhao, Ting, additional, Yan, Chen-Hua, additional, Sun, Yu-Qian, additional, Liu, Kai-Yan, additional, and Huang, Xiao-Jun, additional

Published
2013
Full Text
View/download PDF

120. Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome

Author

Chang, Ying-Jun, primary, Zhao, Xiang-Yu, additional, Xu, Lan-Ping, additional, Liu, Dai-Hong, additional, Liu, Kai-Yan, additional, Chen, Yu-Hong, additional, Wang, Yu, additional, Zhang, Xiao-Hui, additional, Zhao, Xiao-Su, additional, Han, Wei, additional, Chen, Huan, additional, Wang, Feng-Rong, additional, Lv, Meng, additional, and Huang, Xiao-Jun, additional

Published
2013
Full Text
View/download PDF

122. Early Lymphocyte Recovery Predicts Superior Overall Survival After Unmanipulated Haploidentical Blood and Marrow Transplantation for MDS and Acute Myeloid Leukemia Evolving From MDS

Author

Chang, Ying-Jun, primary, Zhao, Xiang-yu, additional, Xu, Lan-ping, additional, Liu, Dai-hong, additional, Liu, Kai-yan, additional, Chen, Yu-hong, additional, Zhao, Xiao-Su, additional, Han, Wei, additional, Chen, Huan, additional, Wang, Feng-rong, additional, Lv, Meng, additional, and Huang, Xiao-jun, additional

Published
2013
Full Text
View/download PDF

125. Incidence of Invasive Fungal Disease After Unmanipulated Haploidentical Stem Cell Transplantation Was Significantly Higher Than That After HLA-Matched Sibling Transplantation

Author

Sun, Yu-qian, primary, Xu, Lan-ping, additional, Liu, Dai-hong, additional, Zhang, Xiao-hui, additional, Han, Wei, additional, Wang, Yu, additional, Chen, Huan, additional, Chen, Yu-hong, additional, Wang, Feng-rong, additional, Wang, Jing-zhi, additional, Ji, Yu, additional, Tang, Fei-fei, additional, Liu, Kai-yan, additional, and Huang, Xiao-jun, additional

Published
2013
Full Text
View/download PDF

128. High-Dose Cyclophosphamide Therapy Associated with Diffuse Alveolar Hemorrhage after Allogeneic Hematopoietic Stem Cell Transplantation

Author

Mo, Xiao-Dong, primary, Xu, Lan-Ping, additional, Liu, Dai-Hong, additional, Zhang, Xiao-Hui, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Han, Wei, additional, Wang, Yu, additional, Wang, Feng-Rong, additional, Wang, Jing-Zhi, additional, Liu, Kai-Yan, additional, and Huang, Xiao-Jun, additional

Published
2012
Full Text
View/download PDF

129. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes

Author

Qin, Ya-Zhen, primary, Zhu, Hong-Hu, additional, Liu, Yan-Rong, additional, Wang, Ya-Zhe, additional, Shi, Hong-Xia, additional, Lai, Yue-Yun, additional, Xu, Lan-Ping, additional, Liu, Dai-Hong, additional, Jiang, Qian, additional, Li, Ling-Di, additional, Jiang, Bin, additional, Liu, Kai-Yan, additional, and Huang, Xiao-Jun, additional

Published
2012
Full Text
View/download PDF

130. All-Trance Retinoid Acid (ATRA) Makes Refractory Immune Thrombocytopenia (RITP) Less Refractory: A Retrospective Study of Ritp Patients Treated with Combination Therapies Including ATRA

Author

Wang, Min, primary, Zhang, Xiao-hui, additional, Han, Wei, additional, Wang, Yu, additional, Liu, Dai-Hong, additional, Xu, Lan-Ping, additional, Liu, Kai-Yan, additional, Fu, Hai-xia, additional, Lv, Meng, additional, Zhou, Yi, additional, and Huang, Xiao-Jun, additional

Published
2012
Full Text
View/download PDF

131. CD58-Negtive Leukemia Initiating Cells Are Independently Associated with High Risk of Relapse in B-Precursor Acute Lymphoblastic Leukemia: A Comprehensive Clinical and Biological Profiling Study

Author

Kong, Yuan, primary, Liu, Yanrong, additional, Zhu, Honghu, additional, Jiang, Qian, additional, Jiang, Hao, additional, Xu, Lan-Ping, additional, Liu, Dai-Hong, additional, Ruan, Guo-Rui, additional, Jiang, Bin, additional, Liu, Kaiyan, additional, and Huang, Xiao-jun, additional

Published
2012
Full Text
View/download PDF

132. Risk-Stratification Treatment Directed by Minimal Residual Disease Improves the Outcome of Acute Myeloid Leukemia with t(8;21) in First Complete Remission: Results of the AML05 Multicentre Trial

Author

Zhu, Honghu, primary, Zhang, Xiao-hui, additional, Qin, Yazhen, additional, Jiang, Hao, additional, Liu, Dai-Hong, additional, Chen, Huan, additional, Jiang, Qian, additional, Chai, Jun-Yue, additional, Wang, Li-Ru, additional, and Huang, Xiaojun, additional

Published
2012
Full Text
View/download PDF

134. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia

Author

Wang, Yu, primary, Liu, Dai-Hong, additional, Liu, Kai-Yan, additional, Xu, Lan-Ping, additional, Zhang, Xiao-Hui, additional, Han, Wei, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Wang, Feng-Rong, additional, Wang, Jing-Zhi, additional, Sun, Yu-Qian, additional, and Huang, Xiao-Jun, additional

Published
2012
Full Text
View/download PDF

135. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates

Author

Zhang, Xiao-hui, primary, Xu, Lan-ping, additional, Liu, Dai-hong, additional, Chen, Huan, additional, Han, Wei, additional, Chen, Yu-hong, additional, Wang, Feng-rong, additional, Wang, Jing-zhi, additional, Wang, Yu, additional, Zhao, Ting, additional, Chen, Yao, additional, Fu, Hai-xia, additional, Liu, Kai-yan, additional, and Huang, Xiao-jun, additional

Published
2012
Full Text
View/download PDF

140. Imatinib Mesylate Is Superior to Allogeneic Hematopoietic Stem Cell Transplantation As the First-Line Therapy for Patients with Chronic Myeloid Leukemia in the Early Chronic Phase

Author

Jiang, Qian, primary, Xu, Lan-Ping, additional, Liu, Dai-Hong, additional, Liu, Kai-Yan, additional, Jiang, Bin, additional, Zhang, Xiao-hui, additional, Wang, Yu, additional, Chen, Shan-Shan, additional, Mo, Xiao-Dong, additional, Zhao, Xiang-Yu, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Han, Wei, additional, Jiang, Hao, additional, Qin, Ya-Zhen, additional, Liu, Yan-Rong, additional, Lai, Yue-yun, additional, Shi, Hong-Xia, additional, Lv, Meng, additional, and Huang, Xiao Jun, additional

Published
2011
Full Text
View/download PDF

141. The effect of HLA disparity on clinical outcome after HLA‐haploidentical blood and marrow transplantation

Author

Huo, Ming‐Rui, primary, Xu, Lan‐Ping, additional, D, Li, additional, Liu, Dai‐Hong, additional, Liu, Kai‐Yan, additional, Chen, Huan, additional, Han, Wei, additional, Chen, Yu‐Hong, additional, Y, Wang, additional, Wang, Jing‐Zhi, additional, Zhang, Xiao‐Hui, additional, Zhao, Xiang‐Yu, additional, and Huang, Xiao‐Jun, additional

Published
2011
Full Text
View/download PDF

143. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

Author

Jiang, Qian, primary, Xu, Lan-Ping, additional, Liu, Dai-Hong, additional, Liu, Kai-Yan, additional, Chen, Shan-Shan, additional, Jiang, Bin, additional, Jiang, Hao, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Han, Wei, additional, Zhang, Xiao-Hui, additional, Wang, Yu, additional, Qin, Ya-Zhen, additional, Liu, Yan-Rong, additional, Lai, Yue-Yun, additional, and Huang, Xiao-Jun, additional

Published
2011
Full Text
View/download PDF

145. Imatinib Mesylate Versus Allogeneic HSCT for Patients with Chronic Myelogenous Leukemia In Accelerated Phase: A Single Center Experience In China After a 9-Year Follow-up

Author

Jiang, Qian, primary, Xu, Lan-Ping, additional, Liu, Dai-Hong, additional, Liu, Kaiyan, additional, Chen, Shan-Shan, additional, Jiang, Bin, additional, Jiang, Hao, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Han, Wei, additional, Zhang, Xiao-hui, additional, Wang, Yu, additional, Qin, Ya-Zhen, additional, Liu, Yan-Rong, additional, Lai, Yue-yun, additional, and Huang, Xiao Jun, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results